On August 3rd in Melbourne, Australia, ASBM Steering Committee member Andrew Spiegel, Executive Director of the Global Colon Cancer Association, presented a poster at the 2017 Annual Scientific Meeting of the Medical Oncology Group of Australia (MOGA).

Nearly 400 Australian medical oncologists gathered for this meeting, themed Real World Oncology: Translating Discovery in to PracticeView the poster here. 

Mr. Spiegel discusses the Australian survey findings with a conference attendee.

Mr. Spiegel reviewed data from the ASBM’s Australian survey, ASBM’s most recent physician survey. The poster presentation specifically focused on the oncology subset which showed that 80% of respondents feel that it is either “Very Important” or “Critically Important” for them to decide which biologic is dispensed to their patient. Furthermore, most (83%) also feel that it is either “Very Important” or “Critically Important” that they be notified if the prescribed biologic medicine has been substituted.

Mr. Spiegel further explained the policy implications behind the data and how ASBM advocates in Australia and around the world to further physician’s perspectives on these issues.